- Home
- PR vs RVMD Comparison
PR vs RVMD Comparison
Compare PR & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PR | RVMD |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 15.2B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | PR | RVMD |
|---|---|---|
| Price | $19.32 | $95.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | $20.31 | ★ $114.63 |
| AVG Volume (30 Days) | ★ 11.8M | 1.6M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $5,065,211,000.00 | N/A |
| Revenue This Year | $5.54 | N/A |
| Revenue Next Year | $11.09 | $454.85 |
| P/E Ratio | $14.92 | ★ N/A |
| Revenue Growth | ★ 1.29 | N/A |
| 52 Week Low | $10.62 | $29.17 |
| 52 Week High | $19.64 | $124.49 |
Technical Indicators
Market Signals| Indicator | PR | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 66.64 | 39.16 |
| Support Level | $12.43 | $93.59 |
| Resistance Level | N/A | $107.45 |
| Average True Range (ATR) | 0.60 | 3.80 |
| MACD | -0.01 | -0.82 |
| Stochastic Oscillator | 88.38 | 1.39 |
Price Performance
Historical ComparisonAbout PR Permian Resources Corporation
Permian Resources Corp is an independent oil and natural gas company focused on generating outsized returns to stakeholders through the responsible acquisition, optimization, and development of oil and liquids-rich natural gas assets. The Company's assets and operations are concentrated in the core of the Permian Basin, and its properties consist of large, contiguous acreage blocks located in West Texas and New Mexico.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.